Search
Aprindine
go.drugbank.com/drugs/DB01429ExperimentalAprindine is a cardiac depressant used in arrhythmias.
Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IbSYN-101
go.drugbank.com/drugs/DB05958ExperimentalSYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells. … SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer.
Pipendoxifene
go.drugbank.com/drugs/DB05414InvestigationalPipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment … ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer.
VLTS-934
go.drugbank.com/drugs/DB05597InvestigationalIt was under investigation in clinical trial NCT00113009 (Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease). … VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).
XTL-6865
go.drugbank.com/drugs/DB06058InvestigationalIt is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.
XP12B
go.drugbank.com/drugs/DB04928InvestigationalXP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.
Potassium guaiacolsulfonate
go.drugbank.com/drugs/DB13735ApprovedWithdrawnGuaiacolsulfonate is an aromatic sulfonic acid. Potassium guaiacolsulfonate salt is an expectorant that thins the mucus in the lungs and reduces chest congestion.
Aranidipine
go.drugbank.com/drugs/DB09229Experimental[A31895] It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.[T88] … It is a calcium antagonist with the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate.
SB-509
go.drugbank.com/drugs/DB05579InvestigationalSB-509 is under investigation in multiple clinical trials for the treatment of Diabetic Neuropathy.